Asthma control, indicators of acute exacerbations and healthcare utilisation overall and by short-acting beta agonist (SABA) overuse versus non-overuse (n=375)
| Asthma control | Overall n=375 | SABA overuse | ||
| No n=104 | Yes n=271 | P value | ||
| Asthma symptom control (GINA-defined) | ||||
| Well controlled | 66 (17.6) | 50 (48.1) | 16 (5.9) | <0.001 |
| Partly controlled | 133 (35.5) | 38 (36.5) | 95 (35.1) | |
| Uncontrolled | 176 (46.9) | 16 (15.4) | 160 (59) | |
| Acute exacerbations* | ||||
| Oral steroid use for worsening asthma | ||||
| ≥1 | 85 (22.7) | 14 (13.5) | 71 (26.2) | 0.01 |
| Emergency presentations or hospitalisation due to asthma | ||||
| ≥1 | 46 (12.3) | 9 (8.7) | 37 (13.7) | 0.279 |
| Doctor visit due to asthma | ||||
| ≥1 | 267 (71.2) | 65 (62.5) | 202 (74.5) | 0.01 |
*In the previous 12 months.
GINA, Global Initiative for Asthma-defined control.